Next Article in Journal
Recent Advances in the Design of Topical Ophthalmic Delivery Systems in the Treatment of Ocular Surface Inflammation and Their Biopharmaceutical Evaluation
Next Article in Special Issue
In Vitro Bioeffects of Polyelectrolyte Multilayer Microcapsules Post-Loaded with Water-Soluble Cationic Photosensitizer
Previous Article in Journal
Microneedle-Based Delivery: An Overview of Current Applications and Trends
Previous Article in Special Issue
Adjuvant Drug-Assisted Bone Healing: Advances and Challenges in Drug Delivery Approaches
Open AccessReview

Injectable Lipid-Based Depot Formulations: Where Do We Stand?

Pharmaceutical Technology Research Group, Department of Chemistry and Biochemistry, University of Bern, Freiestrasse 3, 3012 Bern, Switzerland
*
Author to whom correspondence should be addressed.
Pharmaceutics 2020, 12(6), 567; https://doi.org/10.3390/pharmaceutics12060567
Received: 27 May 2020 / Revised: 13 June 2020 / Accepted: 15 June 2020 / Published: 19 June 2020
The remarkable number of new molecular entities approved per year as parenteral drugs, such as biologics and complex active pharmaceutical ingredients, calls for innovative and tunable drug delivery systems. Besides making these classes of drugs available in the body, injectable depot formulations offer the unique advantage in the parenteral world of reducing the number of required injections, thus increasing effectiveness as well as patient compliance. To date, a plethora of excipients has been proposed to formulate depot systems, and among those, lipids stand out due to their unique biocompatibility properties and safety profile. Looking at the several long-acting drug delivery systems based on lipids designed so far, a legitimate question may arise: How far away are we from an ideal depot formulation? Here, we review sustained release lipid-based platforms developed in the last 5 years, namely oil-based solutions, liposomal systems, in situ forming systems, solid particles, and implants, and we critically discuss the requirements for an ideal depot formulation with respect to the used excipients, biocompatibility, and the challenges presented by the manufacturing process. Finally, we delve into lights and shadows originating from the current setups of in vitro release assays developed with the aim of assessing the translational potential of depot injectables. View Full-Text
Keywords: injectable lipid depot; long-acting drug delivery system; oil-based solutions; liposomes; in situ forming systems; implants; solid particles injectable lipid depot; long-acting drug delivery system; oil-based solutions; liposomes; in situ forming systems; implants; solid particles
Show Figures

Figure 1

MDPI and ACS Style

Rahnfeld, L.; Luciani, P. Injectable Lipid-Based Depot Formulations: Where Do We Stand? Pharmaceutics 2020, 12, 567.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop